Immunome Doses First Patient in IM-1617 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Immunome announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's proprietary TOP1 inhibitor payload.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNM
Wall Street analysts forecast IMNM stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.530
Low
21.00
Averages
33.20
High
40.00
Current: 18.530
Low
21.00
Averages
33.20
High
40.00
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunome Initiates Phase 1 Trial for IM-1617 ADC
- Trial Initiation: Immunome announced that the first patient has been dosed in the Phase 1 trial of IM-1617, an antibody-drug conjugate (ADC) aimed at assessing safety and preliminary anti-tumor activity, marking a significant advancement in targeted cancer therapies.
- Drug Mechanism: IM-1617 incorporates Immunome's proprietary topoisomerase I inhibitor HC74 and targets an undisclosed solid tumor receptor, with preclinical studies demonstrating impressive tumor regression across various models, indicating substantial clinical potential.
- Future Plans: Immunome plans to submit investigational new drug (IND) applications for IM-1340 and IM-1335 in mid and late 2026, respectively, reflecting the company's ongoing momentum and strategic focus in oncology drug development.
- Market Outlook: As IM-1617 progresses through clinical trials, Immunome anticipates strengthening its market position in targeted cancer therapies, providing innovative treatment options for patients and driving long-term growth for the company.
See More
Immunome Q1 Earnings Beat Expectations
- Earnings Surprise: Immunome reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.09, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Immunome's cash and cash equivalents totaled $582.7 million, which is expected to fund operations into 2028, ensuring continuity in research and operational activities.
- Optimistic Future Outlook: The company anticipates an upcoming New Drug Application (NDA) that could drive future revenue growth, enhancing market expectations for its valuation and potentially attracting more investor interest.
- Investment Case Analysis: Seeking Alpha's quantitative rating on Immunome reflects positive market sentiment, and combined with historical financial data, underscores the company's potential and investment value in the biopharmaceutical sector.
See More
Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results
- Clinical Trial Success: Immunome's Phase 3 RINGSIDE trial demonstrated a significant improvement in progression-free survival for varegacestat compared to placebo, with a hazard ratio of 0.16 (p<0.0001), providing robust data support for the New Drug Application and potentially transforming treatment options for adult patients.
- Significant Efficacy: The trial achieved a confirmed objective response rate of 56%, markedly higher than the 9% in the placebo group (p<0.0001), indicating that varegacestat has substantial clinical significance in treating progressing desmoid tumors, which may enhance patients' quality of life.
- Good Safety Profile: Although 82% of participants experienced adverse events like diarrhea, most were grade 1 or 2, indicating that varegacestat has a favorable safety and tolerability profile, making it an attractive treatment option.
- Future Outlook: Immunome plans to present detailed RINGSIDE data at the 2026 ASCO Annual Meeting, which could further elevate market interest in varegacestat and potentially drive its application in cancer treatment.
See More
Immunome CSO Sells Shares Under 10b5-1 Plan
- Transaction Overview: Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock on April 2, 2026, for a total value of $204,238.32, indicating a strategic approach to liquidity management.
- Ownership Changes: This sale reduced Higgins's direct holdings by 30.02%, from 31,438 to 22,000 shares, while his indirect holdings remained unchanged, reflecting his continued confidence in the company's future.
- Transaction Context: The sale was executed under a pre-arranged 10b5-1 trading plan established in December 2025, suggesting it was a routine liquidity management action rather than a market-timing decision, highlighting Higgins's financial diversification strategy.
- Company Outlook: Immunome is advancing its antibody therapeutic programs, particularly IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2, with a New Drug Application submission planned for Q2 2026, showcasing the company's strong growth potential in the biotechnology sector.
See More
Immunome Executive Share Sale Details
- Share Sale Overview: Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares of common stock on April 2, 2026, for approximately $204,000, representing 30.02% of his holdings, highlighting his focus on financial diversification.
- Holding Changes: Post-sale, Higgins holds 22,000 shares directly and 3,000 shares indirectly, with a direct holding valued at roughly $480,000, indicating substantial ongoing investment in the company.
- Trading Plan Context: The sale was executed under a pre-established 10b5-1 trading plan set up in December 2025, locking in the timing and price, which suggests a strategic financial decision rather than a reaction to market conditions.
- Company Growth Prospects: Immunome is advancing its ADC-heavy pipeline, particularly with varegacestat's Phase 3 RINGSIDE trial hitting its primary endpoint in December 2025, with an NDA submission planned for Q2 2026, showcasing the company's potential in antibody therapeutics.
See More
Immunome Grants Stock Options to New Employees
- Stock Option Grant: On March 2, 2026, Immunome granted a total of 282,000 non-statutory stock options to seven new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive position in cancer therapy.
- Exercise Price Setting: Each stock option has an exercise price of $22.21, equal to the closing price on March 2, 2026, which helps incentivize employees to grow with the company, increasing their sense of belonging and motivation.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary of the grant and the remainder vesting monthly, ensuring continued employee contributions during their service, thus enhancing team stability.
- Incentive Plan Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to compliance and transparency in talent acquisition and incentives, which helps boost investor confidence.
See More
Immunome Initiates Phase 1 Trial for IM-1617 ADC
- Trial Initiation: Immunome announced that the first patient has been dosed in the Phase 1 trial of IM-1617, an antibody-drug conjugate (ADC) aimed at assessing safety and preliminary anti-tumor activity, marking a significant advancement in targeted cancer therapies.
- Drug Mechanism: IM-1617 incorporates Immunome's proprietary topoisomerase I inhibitor HC74 and targets an undisclosed solid tumor receptor, with preclinical studies demonstrating impressive tumor regression across various models, indicating substantial clinical potential.
- Future Plans: Immunome plans to submit investigational new drug (IND) applications for IM-1340 and IM-1335 in mid and late 2026, respectively, reflecting the company's ongoing momentum and strategic focus in oncology drug development.
- Market Outlook: As IM-1617 progresses through clinical trials, Immunome anticipates strengthening its market position in targeted cancer therapies, providing innovative treatment options for patients and driving long-term growth for the company.
See More
Immunome Q1 Earnings Beat Expectations
- Earnings Surprise: Immunome reported a Q1 GAAP EPS of -$0.48, beating expectations by $0.09, indicating an improvement in financial performance that could bolster investor confidence.
- Strong Cash Position: As of March 31, 2026, Immunome's cash and cash equivalents totaled $582.7 million, which is expected to fund operations into 2028, ensuring continuity in research and operational activities.
- Optimistic Future Outlook: The company anticipates an upcoming New Drug Application (NDA) that could drive future revenue growth, enhancing market expectations for its valuation and potentially attracting more investor interest.
- Investment Case Analysis: Seeking Alpha's quantitative rating on Immunome reflects positive market sentiment, and combined with historical financial data, underscores the company's potential and investment value in the biopharmaceutical sector.
See More
Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results
- Clinical Trial Success: Immunome's Phase 3 RINGSIDE trial demonstrated a significant improvement in progression-free survival for varegacestat compared to placebo, with a hazard ratio of 0.16 (p<0.0001), providing robust data support for the New Drug Application and potentially transforming treatment options for adult patients.
- Significant Efficacy: The trial achieved a confirmed objective response rate of 56%, markedly higher than the 9% in the placebo group (p<0.0001), indicating that varegacestat has substantial clinical significance in treating progressing desmoid tumors, which may enhance patients' quality of life.
- Good Safety Profile: Although 82% of participants experienced adverse events like diarrhea, most were grade 1 or 2, indicating that varegacestat has a favorable safety and tolerability profile, making it an attractive treatment option.
- Future Outlook: Immunome plans to present detailed RINGSIDE data at the 2026 ASCO Annual Meeting, which could further elevate market interest in varegacestat and potentially drive its application in cancer treatment.
See More
Immunome CSO Sells Shares Under 10b5-1 Plan
- Transaction Overview: Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock on April 2, 2026, for a total value of $204,238.32, indicating a strategic approach to liquidity management.
- Ownership Changes: This sale reduced Higgins's direct holdings by 30.02%, from 31,438 to 22,000 shares, while his indirect holdings remained unchanged, reflecting his continued confidence in the company's future.
- Transaction Context: The sale was executed under a pre-arranged 10b5-1 trading plan established in December 2025, suggesting it was a routine liquidity management action rather than a market-timing decision, highlighting Higgins's financial diversification strategy.
- Company Outlook: Immunome is advancing its antibody therapeutic programs, particularly IMM-ONC-01 for cancer and IMM-BCP-01 for SARS-CoV-2, with a New Drug Application submission planned for Q2 2026, showcasing the company's strong growth potential in the biotechnology sector.
See More
Immunome Executive Share Sale Details
- Share Sale Overview: Jack Higgins, Chief Scientific Officer of Immunome, sold 9,438 shares of common stock on April 2, 2026, for approximately $204,000, representing 30.02% of his holdings, highlighting his focus on financial diversification.
- Holding Changes: Post-sale, Higgins holds 22,000 shares directly and 3,000 shares indirectly, with a direct holding valued at roughly $480,000, indicating substantial ongoing investment in the company.
- Trading Plan Context: The sale was executed under a pre-established 10b5-1 trading plan set up in December 2025, locking in the timing and price, which suggests a strategic financial decision rather than a reaction to market conditions.
- Company Growth Prospects: Immunome is advancing its ADC-heavy pipeline, particularly with varegacestat's Phase 3 RINGSIDE trial hitting its primary endpoint in December 2025, with an NDA submission planned for Q2 2026, showcasing the company's potential in antibody therapeutics.
See More
Immunome Grants Stock Options to New Employees
- Stock Option Grant: On March 2, 2026, Immunome granted a total of 282,000 non-statutory stock options to seven new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive position in cancer therapy.
- Exercise Price Setting: Each stock option has an exercise price of $22.21, equal to the closing price on March 2, 2026, which helps incentivize employees to grow with the company, increasing their sense of belonging and motivation.
- Vesting Schedule: The stock options will vest over four years, with 25% vesting on the one-year anniversary of the grant and the remainder vesting monthly, ensuring continued employee contributions during their service, thus enhancing team stability.
- Incentive Plan Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), indicating the company's commitment to compliance and transparency in talent acquisition and incentives, which helps boost investor confidence.
See More
